-
Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe [Elektronski vir] : a Central European Cooperative Oncology Group analysisČufer, Tanja, 1955- ...Background. Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite ... accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel drugs for NSCLC are poorly accessible in Central and Eastern European (CEE) countries. Material and Methods. The Central European Cooperative Oncology Group conducted a survey among experts from 10 CEE countries to provide an overview on the availability of novel drugs for NSCLC and time from registration to reimbursement decision in their countries. Results. Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries, for other registered therapies - even for ALK inhibitors and checkpoint inhibitors in first-line - there were apparent gaps in availability and/or reimbursement. There was a trend for better availability of drugs with longer time from EMA marketing authorization. Substantial differences in access to novel drugs among CEE countries were observed. In general, the availability of drugs is not in accordance with the Magnitude of Clinical Benefit Scale (MCBS), as defined by the European Society for Medical Oncology (ESMO). Time spans between drug registrations and national decisions on reimbursement vary greatly, from less than 3 months in one country to more than 1 year in the majority of countries. Conclusion. The access to novel drugs for NSCLC in CEE countries is suboptimal. To enable access to the most effective compounds within the shortest possible time, reimbursement decisions should be faster and ESMO MCBS should be incorporated into decision making.Source: The oncologist [Elektronski vir]. - ISSN 1549-490X (Vol. 25, iss. 3, Mar. 2020, str. e598-e601)Type of material - e-article ; adult, seriousPublish date - 2020Language - englishCOBISS.SI-ID - 2048592241
Author
Čufer, Tanja, 1955- |
Ciuleanu, Tudor |
Berzinec, Peter |
Galffy, Gabriela |
Jakopović, Marko |
Jassem, Jacek |
Jovanovic, Dragana |
MIhaylova, Zhasmina |
Ostoros, Gyula |
Thallinger, Christiane |
Zemanova, Milada |
Zielinski, Christoph
Topics
Carcinoma, non-small cell lung |
Therapy |
Europe |
Eastern Europe |
Drug therapy |
Europe |
Eastern Europe |
Nedrobnocelični karcinom pljuč |
Terapija |
Evropa |
Vzhodna Evropa |
Terapija z zdravili |
Evropa |
Vzhodna Evropa |
nedrobnocelični rak pljuč |
zdravljenje |
nova zdravila |
Srednja Evropa |
Jugovzhodna Evropa |
non-small cell lung cancer |
treatment |
novel drugs |
Central Europe |
Southeastern Europe
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Čufer, Tanja, 1955- | 12179 |
Ciuleanu, Tudor | ![]() |
Berzinec, Peter | ![]() |
Galffy, Gabriela | ![]() |
Jakopović, Marko | ![]() |
Jassem, Jacek | ![]() |
Jovanovic, Dragana | ![]() |
MIhaylova, Zhasmina | ![]() |
Ostoros, Gyula | ![]() |
Thallinger, Christiane | ![]() |
Zemanova, Milada | ![]() |
Zielinski, Christoph | ![]() |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.